Voronoi Past Earnings Performance

Past criteria checks 0/6

Voronoi's earnings have been declining at an average annual rate of -5.4%, while the Biotechs industry saw earnings growing at 3.8% annually. Revenues have been declining at an average rate of 28.5% per year.

Key information

-5.4%

Earnings growth rate

6.4%

EPS growth rate

Biotechs Industry Growth	11.7%
Revenue growth rate	-28.5%
Return on equity	-52.2%
Net Margin	n/a
Last Earnings Update	30 Sep 2024

Recent past performance updates

Recent updates

Health Check: How Prudently Does Voronoi (KOSDAQ:310210) Use Debt?

Sep 20

Is Voronoi (KOSDAQ:310210) Using Too Much Debt?

May 28

Revenue & Expenses Breakdown

How Voronoi makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

KOSDAQ:A310210 Revenue, expenses and earnings (KRW Millions)
Date	Revenue	Earnings	G+A Expenses	R&D Expenses
30 Sep 24	0	-38,879	15,164	17,322
30 Jun 24	0	-36,066	14,628	14,815
31 Mar 24	0	-35,040	14,013	13,484
31 Dec 23	0	-36,848	13,816	14,464
30 Sep 23	589	-30,991	13,483	13,900
30 Jun 23	7,943	-22,876	13,117	13,862
31 Mar 23	8,630	-22,143	12,843	13,326
31 Dec 22	9,768	-19,900	12,599	11,727
30 Sep 22	13,845	-14,095	12,252	11,316
30 Jun 22	12,167	-18,108	12,139	13,402
31 Mar 22	14,419	-18,833	11,611	13,121
31 Dec 21	14,784	-15,096	9,650	12,492
30 Sep 21	16,095	-12,472	10,233	11,913
31 Dec 20	6,180	-23,187	16,262	13,412
31 Dec 19	301	-50,003	20,166	31,498
31 Dec 18	174	-9,218	3,518	7,047
31 Dec 17	34	-1,882	1,687	724

Quality Earnings: A310210 is currently unprofitable.

Growing Profit Margin: A310210 is currently unprofitable.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: A310210 is unprofitable, and losses have increased over the past 5 years at a rate of 5.4% per year.

Accelerating Growth: Unable to compare A310210's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: A310210 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (7.9%).

Return on Equity

High ROE: A310210 has a negative Return on Equity (-52.17%), as it is currently unprofitable.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2024/12/30 15:29
End of Day Share Price	2024/12/30 00:00
Earnings	2024/09/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Voronoi, Inc. is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Hyun-soo Ha	Yuanta Securities Korea Co., Ltd.